These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

155 related items for PubMed ID: 17384500

  • 1. Long-term erythropoietin therapy does not affect metalloproteinases and their inhibitor levels, oxidative stress and inflammation in hemodialyzed patients.
    Pawlak K, Pawlak D, Mysliwiec M.
    Am J Nephrol; 2007; 27(3):221-5. PubMed ID: 17384500
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. [Chronic inflammation, oxidative stress and effects of erythropoetin in end-stage renal disease patients].
    Lazarević T, Stojimirović B, Poskurica M, Lazarević M, Mitrović N, Stolić R.
    Med Pregl; 2007; 60 Suppl 2():109-13. PubMed ID: 18928173
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Long-term erythropoietin therapy decreases CC-chemokine levels and intima-media thickness in hemodialyzed patients.
    Pawlak K, Pawlak D, Mysliwiec M.
    Am J Nephrol; 2006; 26(5):497-502. PubMed ID: 17119331
    [Abstract] [Full Text] [Related]

  • 6. Red blood cell membrane lipid peroxidation and resistance to erythropoietin therapy in hemodialysis patients.
    Gallucci MT, Lubrano R, Meloni C, Morosetti M, Manca di Villahermosa S, Scoppi P, Palombo G, Castello MA, Casciani CU.
    Clin Nephrol; 1999 Oct; 52(4):239-45. PubMed ID: 10543326
    [Abstract] [Full Text] [Related]

  • 7. Effects of long-term erythropoietin therapy on fibrinolytic system in haemodialyzed patients.
    Pawlak K, Pawlak D, Mysliwiec M.
    Thromb Res; 2008 Oct; 121(6):787-91. PubMed ID: 17869326
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Influence of oxidative stress and inflammation on rHuEPO requirements of hemodialysis patients with CRP values "in normal range".
    Tutal E, Sezer S, Bilgic A, Aldemir D, Turkoglu S, Demirel O, Ozdemir N, Haberal M.
    Transplant Proc; 2007 Dec; 39(10):3035-40. PubMed ID: 18089316
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Effect of erythropoietin therapy and selenium supplementation on selected antioxidant parameters in blood of uremic patients on long-term hemodialysis.
    Adamowicz A, Trafikowska U, Trafikowska A, Zachara B, Manitius J.
    Med Sci Monit; 2002 Mar; 8(3):CR202-5. PubMed ID: 11887037
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Reactive oxygen metabolites: a link between oxidative stress and inflammation in patients on hemodialysis.
    Samouilidou E, Grapsa E, Karpouza A, Lagouranis A.
    Blood Purif; 2007 Mar; 25(2):175-8. PubMed ID: 17215574
    [Abstract] [Full Text] [Related]

  • 19. Urokinase-type plasminogen activator and metalloproteinase-2 are independently related to the carotid atherosclerosis in haemodialysis patients.
    Pawlak K, Pawlak D, Myśliwiec M.
    Thromb Res; 2008 Mar; 121(4):543-8. PubMed ID: 17706748
    [Abstract] [Full Text] [Related]

  • 20. [Recombinant human erythropoietin (rh-EPO) in chronic, dialysis-dependent renal failure: effects on macro- and microcirculation and hematologic parameters].
    Köhler M, Mörsdorf S, Jung F, Braun B, Waldhausen P, Pindur G, Weber U, Bosslet R, Bambauer R, Jutzler GA.
    Beitr Infusionsther; 1990 Mar; 26():89-95. PubMed ID: 1703909
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.